BridgeBio Pharma Long Term Debt 2018-2024 | BBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BridgeBio Pharma long term debt from 2018 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BridgeBio Pharma long term debt from 2018 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19B
Dr Reddy's Laboratories (RDY)	$12B
Bausch Health Cos (BHC)	$3B
Amphastar Pharmaceuticals (AMPH)	$2.1B
Supernus Pharmaceuticals (SUPN)	$2B
Taysha Gene Therapies (TSHA)	$434M
Personalis (PSNL)	$261M
Assembly Biosciences (ASMB)	$98M
Sol-Gel Technologies (SLGL)	$12M
Evoke Pharma (EVOK)	$7M
Teligent (TLGT)	$0M